Form 8-K EAGLE PHARMACEUTICALS, For: Aug 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 9c; Approves $75M Stock Buyback Plan
August 9, 2016 6:51 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of $0.80, $0.09 better than the analyst estimate of $0.71. Revenue for the quarter came in at $40.9 million versus the consensus estimate of $40.8 million.
On August 2, 2016, the Board of Directors has approved a share repurchase program, under... More
Eagle Pharmaceuticals (EGRX) Announces Positive Results from Ryanodex NDA Meeting w/ FDA
August 9, 2016 6:46 AM EDTEagle Pharmaceuticals (Nasdaq: EGRX) announced that the U.S. Food and Drug Administration ("FDA") has determined that no additional human safety and efficacy data is required for the submission of Eagles New Drug Application (NDA) for Ryanodex® for the treatment of exertional heat stroke (EHS), an investigational new indication for the product, further confirming that a hybrid development program comprised of clinical data from EHS patients and preclinical data from animal studies constitutes an adequate regulatory pathway for the NDA submission.
Eagle has also reduced its future Ryanodex royalty obligations to its licensing... More
